AGL 5.60 Decreased By ▼ -0.18 (-3.11%)
ANL 8.90 Increased By ▲ 0.02 (0.23%)
AVN 76.85 Decreased By ▼ -2.07 (-2.62%)
BOP 5.26 Decreased By ▼ -0.02 (-0.38%)
CNERGY 4.63 Decreased By ▼ -0.07 (-1.49%)
EFERT 81.27 Decreased By ▼ -0.33 (-0.4%)
EPCL 50.08 Decreased By ▼ -0.83 (-1.63%)
FCCL 13.16 Decreased By ▼ -0.22 (-1.64%)
FFL 5.69 Decreased By ▼ -0.03 (-0.52%)
FLYNG 7.07 Decreased By ▼ -0.08 (-1.12%)
FNEL 4.79 Decreased By ▼ -0.03 (-0.62%)
GGGL 8.80 Decreased By ▼ -0.10 (-1.12%)
GGL 14.55 Decreased By ▼ -1.33 (-8.38%)
HUMNL 5.69 Decreased By ▼ -0.08 (-1.39%)
KEL 2.63 Decreased By ▼ -0.03 (-1.13%)
LOTCHEM 28.60 Decreased By ▼ -0.45 (-1.55%)
MLCF 24.49 Decreased By ▼ -0.61 (-2.43%)
OGDC 72.43 Decreased By ▼ -0.02 (-0.03%)
PAEL 15.36 Increased By ▲ 0.01 (0.07%)
PIBTL 5.00 Decreased By ▼ -0.05 (-0.99%)
PRL 16.10 Decreased By ▼ -0.19 (-1.17%)
SILK 1.08 Decreased By ▼ -0.01 (-0.92%)
TELE 9.14 Decreased By ▼ -0.23 (-2.45%)
TPL 7.23 Decreased By ▼ -0.10 (-1.36%)
TPLP 18.61 Decreased By ▼ -0.34 (-1.79%)
TREET 21.68 Decreased By ▼ -0.32 (-1.45%)
TRG 136.71 Decreased By ▼ -4.44 (-3.15%)
UNITY 16.88 Decreased By ▼ -0.14 (-0.82%)
WAVES 9.86 Decreased By ▼ -0.04 (-0.4%)
WTL 1.41 No Change ▼ 0.00 (0%)
BR100 4,225 Decreased By -29.6 (-0.7%)
BR30 15,518 Decreased By -214.7 (-1.36%)
KSE100 42,150 Decreased By -243.4 (-0.57%)
KSE30 15,588 Decreased By -75.7 (-0.48%)
World

Spain extends AstraZeneca dose gap to 16 weeks, beyond EU approved limit

  • The EMA's approval for the vaccine is based on the second dose being administered between four and 12 weeks after the first. A 16-week interval has not been tested in any human trials.
  • Spain's state-backed Carlos III Health Institute is investigating the effects of giving Pfizer and BioNTech's vaccine to patients who already received an AstraZeneca shot.
Published April 30, 2021
Follow us

MADRID: Spain is extending the gap between the first and second doses of AstraZeneca's COVID-19 vaccine to 16 weeks for people aged under 60, the government said on Friday, going beyond the 12-week maximum interval approved by European authorities.

Spain is the first country to diverge from the European Medicines Agency's authorisation and promote "off label use", which would not be approved by the regulator and would leave individual nations responsible for any possible side-effects.

The extension gives authorities more breathing space to determine the safest way to administer the vaccine, the health ministry said. Spain initially gave AstraZeneca shots to essential workers aged 18-65 before allowing only people aged over 60 to received the vaccine due to concerns about blood clots in younger people.

The EMA's approval for the vaccine is based on the second dose being administered between four and 12 weeks after the first. A 16-week interval has not been tested in any human trials.

AstraZeneca and the EMA did not immediately respond to requests for comment.

Spain's move to restrict use of the shot caused widespread uncertainty and meant some younger people who had already received a first dose have been excluded from getting a second. By extending the interval between doses, authorities will be able to evaluate the results of trials on mixing different vaccines before deciding whether those groups will receive a second AstraZeneca shot or another drug, the ministry said.

Spain's state-backed Carlos III Health Institute is investigating the effects of giving Pfizer and BioNTech's vaccine to patients who already received an AstraZeneca shot.

Comments

Comments are closed.

Spain extends AstraZeneca dose gap to 16 weeks, beyond EU approved limit

IK says will dissolve assemblies ‘very soon’

Provinces’ power sector schemes: Rs8.11bn approved by ECC

Effective Nov 2022: Agri consumers of Discos, KE have to pay Rs23.30/unit

PTI Sindh MPAs hand in their resignations

Dues against consumer billing collection: KE seeks MoF’s help for release of over Rs4.5bn collected by Pakistan Post

COAS urged to disassociate himself from Bajwa’s ‘controversial’ actions

Public limited companies: Conditions for launching REITs schemes laid down

Income tax arrears: Nov collection up Rs2.33bn to Rs8.98bn YoY

Centcom chief, COAS discuss security cooperation

Asset-backed securitization rules: SPVs allowed to offer debt securities